U.S. and European Union Osteoporosis Drugs Market Size and Share Analysis by Type (Bisphosphonates, RANK Ligand Inhibitors, Parathyroid Hormone Therapy, SERMs), Route of Administration (Injectable, Oral & Spray), Application (Primary Osteoporosis, Secondary Osteoporosis) - Industry Demand Forecast to 2030

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Analysis Period

1.4 Market Data Reporting Unit

1.4.1 Value

1.5 Market Size Breakdown by Segment

1.5.1 Market Segmentation by Type

1.5.2 Market Segmentation by Route of Administration

1.5.3 Market Segmentation by Application

1.5.4 Market Segment Analysis of Countries

1.6 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.1.1 Paid

2.1.2 Unpaid

2.1.3 P&S Intelligence Database

2.2 Primary Research

2.2.1 Breakdown of Primary Research, by Designation

2.2.2 Breakdown of Primary Research, by Company Type

2.3 Market Size Estimation

2.4 Data Triangulation

2.5 Currency Conversion Rates

2.6 Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Definition of Market Segments

4.1 By Type

4.1.1 Bisphosphonates

4.1.2 RANKL Inhibitors

4.1.3 Parathyroid Hormone Therapy

4.1.4 SERMs

4.1.5 Others

4.2 By Route of Administration

4.2.1 Injectable

4.2.2 Oral & Spray

4.3 By Application

4.3.1 Primary Osteoporosis

4.3.2 Secondary Osteoporosis

Chapter 5. Industry Outlook

5.1 Market Dynamics

5.1.1 Trends

5.1.1.1 Increasing awareness of osteoporosis care

5.1.2 Drivers

5.1.2.1 Rising prevalence of osteoporosis

5.1.2.2 Surging treatment strategies for osteoporosis

5.1.2.3 Increasing osteoporosis clinical trials pipeline

5.1.2.4 Growing geriatric population

5.1.2.5 Rising healthcare expenditure

5.1.3 Impact Analysis of Drivers on Market Forecast

5.1.4 Restraints

5.1.4.1 Growing gap in treatment options

5.1.4.2 Patent expiration of osteoporosis drugs

5.1.5 Impact Analysis of Restraints on Market Forecast

5.2 Impact of COVID-19

5.3 Porter’s Five Forces Analysis

5.3.1 Bargaining Power of Buyers

5.3.2 Bargaining Power of Suppliers

5.3.3 Intensity of Rivalry

5.3.4 Threat of New Entrants

5.3.5 Threat of Substitutes

Chapter 6. Regulatory Framework for Drug Approval

6.1 U.S.

6.2 Europe

6.2.1 Centralized Procedure

6.2.2 Mutual Recognition Procedure

6.2.3 Decentralized Procedure

6.2.4 Nationalized Procedure

6.3 Japan

Chapter 7. Global Market Size and Forecast

7.1 North America, by Country

7.2 Europe, by Region

Chapter 8. U.S. Market Size and Forecast

8.1 Overview

8.2 Market Revenue, by Type (2019–2030)

8.3 Market Revenue, by Route of Administration (2019–2030)

8.4 Market Revenue, by Application (2019–2030)

Chapter 9. European Union Market Size and Forecast

9.1 Overview

9.2 Market Revenue, by Type (2019–2030)

9.3 Market Revenue, by Route of Administration (2019–2030)

9.4 Market Revenue, by Application (2019–2030)

9.5 Market Revenue, by Country (2019–2030)

Chapter 10. Germany Market Size and Forecast

10.1 Overview

10.2 Market Revenue, by Type (2019–2030)

10.3 Market Revenue, by Route of Administration (2019–2030)

10.4 Market Revenue, by Application (2019–2030)

Chapter 11. France Market Size and Forecast

11.1 Overview

11.2 Market Revenue, by Type (2019–2030)

11.3 Market Revenue, by Route of Administration (2019–2030)

11.4 Market Revenue, by Application (2019–2030)

Chapter 12. Italy Market Size and Forecast

12.1 Overview

12.2 Market Revenue, by Type (2019–2030)

12.3 Market Revenue, by Route of Administration (2019–2030)

12.4 Market Revenue, by Application (2019–2030)

Chapter 13. Spain Market Size and Forecast

13.1 Overview

13.2 Market Revenue, by Type (2019–2030)

13.3 Market Revenue, by Route of Administration (2019–2030)

13.4 Market Revenue, by Application (2019–2030)

Chapter 14. Austria Market Size and Forecast

14.1 Overview

14.2 Market Revenue, by Type (2019–2030)

14.3 Market Revenue, by Route of Administration (2019–2030)

14.4 Market Revenue, by Application (2019–2030)

Chapter 15. Belgium Market Size and Forecast

15.1 Overview

15.2 Market Revenue, by Type (2019–2030)

15.3 Market Revenue, by Route of Administration (2019–2030)

15.4 Market Revenue, by Application (2019–2030)

Chapter 16. Netherlands Market Size and Forecast

16.1 Overview

16.2 Market Revenue, by Type (2019–2030)

16.3 Market Revenue, by Route of Administration (2019–2030)

16.4 Market Revenue, by Application (2019–2030)

Chapter 17. Rest of the EU Market Size and Forecast

17.1 Overview

17.2 Market Revenue, by Type (2019–2030)

17.3 Market Revenue, by Route of Administration (2019–2030)

17.4 Market Revenue, by Application (2019–2030)

Chapter 18. Competitive Landscape

18.1 FDA-Approved Drugs for Osteoporosis Treatment and Prevention

18.2 Competitive Benchmarking of Key Players

18.3 Product Benchmarking of Key Players

18.4 Recent Strategic Developments of Key Players

18.4.1 Product Launches

18.4.2 Partnerships

18.4.3 Other Developments

Chapter 19. Company Profiles

19.1 Eli Lilly and Company

19.1.1 Business Overview

19.1.2 Product and Service Offerings

19.1.3 Key Financial Summary

19.2 Amgen Inc.

19.2.1 Business Overview

19.2.2 Product and Service Offerings

19.2.3 Key Financial Summary

19.3 Aurobindo Pharma

19.3.1 Business Overview

19.3.2 Product and Service Offerings

19.3.3 Key Financial Summary

19.4 Sandoz International GmbH

19.4.1 Business Overview

19.4.2 Product and Service Offerings

19.5 Organon & Co.

19.5.1 Business Overview

19.5.2 Product and Service Offerings

19.5.3 Key Financial Summary

19.6 Cipla Ltd.

19.6.1 Business Overview

19.6.2 Product and Service Offerings

19.6.3 Key Financial Summary

19.7 Polpharma API

19.7.1 Business Overview

19.7.2 Product and Service Offerings

19.8 Teva Pharmaceutical Industries Limited

19.8.1 Business Overview

19.8.2 Product and Service Offerings

19.8.3 Key Financial Summary

19.9 Pfizer Inc.

19.9.1 Business Overview

19.9.2 Product and Service Offerings

19.9.3 Key Financial Summary

19.10 EffRx Pharmaceuticals SA

19.10.1 Business Overview

19.10.2 Product and Service Offerings

19.11 Radius Health Inc.

19.11.1 Business Overview

19.11.2 Product and Service Offerings

19.12 Apotex Inc.

19.12.1 Business Overview

19.12.2 Product and Service Offerings

19.13 Viatris Inc.

19.13.1 Business Overview

19.13.2 Product and Service Offerings

19.13.3 Key Financial Summary

19.14 Sun Pharmaceutical Industries Ltd.

19.14.1 Business Overview

19.14.2 Product and Service Offerings

19.14.3 Key Financial Summary

19.15 Theramex HQ UK Limited

19.15.1 Business Overview

19.15.2 Product and Service Offerings

Chapter 20. Appendix

20.1 Abbreviations

20.2 Sources and References

20.3 Related Reports

 

LIST OF TABLES

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 HEALTHCARE EXPENDITURE AS PERCENTAGE OF GDP

TABLE 3 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 5 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY REGION, $M (2017–2022)

TABLE 6 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY REGION, $M (2023–2027)

TABLE 7 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY REGION, $M (2028–2030)

TABLE 8 NORTH AMERICA OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, $M (2017–2022)

TABLE 9 NORTH AMERICA OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, $M (2023–2027)

TABLE 10 NORTH AMERICA OSTEOPOROSIS DRUGS MARKET, BY COUNTRY, $M (2028–2030)

TABLE 11 EUROPE OSTEOPOROSIS DRUGS MARKET, BY REGION, $M (2017–2022)

TABLE 12 EUROPE OSTEOPOROSIS DRUGS MARKET, BY REGION, $M (2023–2027)

TABLE 13 EUROPE OSTEOPOROSIS DRUGS MARKET, BY REGION, $M (2028–2030)

TABLE 14 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 15 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 16 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 17 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 18 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 19 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 20 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 21 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 22 U.S. OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 23 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 24 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 25 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 26 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 27 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 28 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 29 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 30 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 31 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 32 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2017–2022)

TABLE 33 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2023–2026)

TABLE 34 EUROPEAN UNION OSTEOPOROSIS DRUGS MARKET REVENUE, BY COUNTRY, $M (2027–2030)

TABLE 35 KEY OSTEOPOROSIS STATISTICS IN GERMANY

TABLE 36 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 37 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 38 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 39 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 40 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 41 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 42 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 43 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 44 GERMANY OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 45 KEY OSTEOPOROSIS STATISTICS IN FRANCE

TABLE 46 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 47 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 48 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 49 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 50 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 51 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 52 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 53 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 54 FRANCE OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 55 KEY OSTEOPORORSIS STATISTICS IN ITALY

TABLE 56 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 57 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 58 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 59 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 60 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 61 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 62 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 63 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 64 ITALY OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 65 KEY OSTEOPOROSIS STATISTICS IN SPAIN

TABLE 66 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 67 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 68 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 69 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 70 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 71 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 72 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 73 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 74 SPAIN OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 75 KEY OSTEOPOROSIS STATISTICS IN AUSTRIA

TABLE 76 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 77 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 78 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 79 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 80 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 81 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 82 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 83 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 84 AUSTRIA OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 85 KEY OSTEOPOROSIS STATISTICS IN BELGIUM

TABLE 86 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 87 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 88 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 89 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 90 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)

TABLE 91 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2027–2030)

TABLE 92 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2017–2022)

TABLE 93 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2023–2026)

TABLE 94 BELGIUM OSTEOPOROSIS DRUGS MARKET REVENUE, BY APPLICATION, $M (2027–2030)

TABLE 95 KEY OSTEOPOROSIS STATISTICS IN NETHERLANDS

TABLE 96 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2017–2022)

TABLE 97 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2023–2026)

TABLE 98 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY TYPE, $M (2027–2030)

TABLE 99 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2017–2022)

TABLE 100 NETHERLANDS OSTEOPOROSIS DRUGS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, $M (2023–2026)